An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson's disease medication delivered through an infusion pump is safe and effective at reducing ...

DUOPA is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor fluctuations in advanced Parkinson's disease · In a clinical trial, patients treated with DUOPA ...

An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing ...

Designed for advanced Parkinson’s with poorly controlled motor fluctuations, the infusion delivers steadier levodopa exposure than pills via continuous subcutaneous dosing.

An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing ...

A therapy for Parkinson’s disease that can be delivered by a 24-hour subcutaneous infusion pump has been recommended for use by the NHS and could be an option for hundreds of patients with the ...

The FDA approved a subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson's disease, AbbVie announced Thursday. Foscarbidopa and foslevodopa are ...

In a remarkable advancement in medical care, King’s College Hospital London in Dubai has successfully administered the subcutaneous Levodopa (Fos-levodopa) pump treatment to the youngest Parkinson’s ...

Northwestern Medicine scientists have discovered that targeting neuronal signaling controlling aberrant learning in the striatum may improve the efficacy of a first-line therapy for Parkinson's ...

Among the patients who had post-PEG-J PD diary assessments, one patient did not maintain LCIG monotherapy and started concomitant medication of rotigotine and levodopa on treatment day 60. This ...